Elsevier

Cytokine

Volume 81, May 2016, Pages 77-81
Cytokine

Cyclosporin A significantly improves preeclampsia signs and suppresses inflammation in a rat model

https://doi.org/10.1016/j.cyto.2016.02.014Get rights and content

Highlights

  • Blood pressure and urine protein levels are increased in a LPS-induced preeclampsia rat model.

  • Pro-inflammatory cytokines are also increased in this model.

  • Treatment of symptomatic animals with cyclosporin A reduces blood pressure, urine protein and cytokine levels.

  • Cyclosporin A is a potentially novel therapeutic for treatment of preeclampsia symptoms.

Abstract

Preeclampsia is associated with an increased inflammatory response. Immune suppression might be an effective treatment. The aim of this study was to examine whether Cyclosporin A (CsA), an immunosuppressant, improves clinical characteristics of preeclampsia and suppresses inflammation in a lipopolysaccharide (LPS) induced preeclampsia rat model. Pregnant rats were randomly divided into 4 groups: group 1 (PE) rats each received LPS via tail vein on gestational day (GD) 14; group 2 (PE + CsA5) rats were pretreated with LPS (1.0 μg/kg) on GD 14 and were then treated with CsA (5 mg/kg, ip) on GDs 16, 17 and 18; group 3 (PE + CsA10) rats were pretreated with LPS (1.0 μg/kg) on GD 14 and were then treated with CsA (10 mg/kg, ip) on GDs 16, 17 and 18; group 4 (pregnant control, PC) rats were treated with the vehicle (saline) used for groups 1, 2 and 3. Systolic blood pressure, urinary albumin, biometric parameters and the levels of serum cytokines were measured on day 20. CsA treatment significantly reduced LPS-induced systolic blood pressure and the mean 24-h urinary albumin excretion. Pro-inflammatory cytokines IL-6, IL-17, IFN-γ and TNF-α were increased in the LPS treatment group but were reduced in (LPS + CsA) group (P < 0.05). Anti-inflammatory cytokine IL-4 was decreased in the LPS group but was increased in (LPS + CsA) group (P < 0.05). Cyclosporine A improved preeclampsia signs and attenuated inflammatory responses in the LPS induced preeclampsia rat model which suggests that immunosuppressant might be an alternative management option for preeclampsia.

Introduction

Preeclampsia (PE) is a pregnancy-specific disorder characterized by the new onset of hypertension and proteinuria following 20 weeks of gestation in a previously normotensive woman. It is one of the leading causes of maternal death and a major contributor of maternal and perinatal morbidity worldwide, affecting 2–8% of pregnancies [6], [22]. The only effective treatment for preeclampsia is delivery of the fetus and placenta.

Although many advances have been achieved during the past decades, the precise pathogenesis of this disorder remains elusive. Recently, accumulating evidence indicates that immune system activation and excessive inflammation play a crucial role in the development of preeclampsia [11]. Changes in maternal peripheral blood indicate that pregnancy is associated with a mild yet sustained systemic inflammatory response [17]. Monocytes display increased activation, and this activation seems to be further exaggerated in preeclampsia [13], [16]. Studies have reported increased serum levels of pro-inflammatory cytokines and decreased levels of anti-inflammatory cytokines in women with PE compared to normal pregnancy [15]. Several studies have demonstrated that successful pregnancy is a Th1-Th2 co-operation phenomenon with a predominantly Th2-type lymphocyte response [19]. The imbalance of Th1 and Th2 cells and the alterations of the prevalence of Th17 and regulatory T cells have been related to pregnancy disorders, including preeclampsia [3], [18], [26]. Despite preeclampsia being identified as an exaggerated inflammatory state resulting from an altered immune response, currently, there is no novel and effective treatment for preeclampsia targeting the immune system.

Cyclosporine A (CsA) is an immunosuppressant agent that is widely used in clinical practice, predominantly for the prevention of rejection in various types of post-allogenic organ transplantation [10]. In addition to solid organ transplant prophylaxis, CsA has also been used for the treatment of immune-related disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and a wide variety of other autoimmune diseases [5], [7]. In addition, some studies have focused on immune therapy in reproductive system disorders, such as spontaneous miscarriage [23], [27].

Although CsA is administered routinely for the prevention of rejection in various types of post-allogenic organ transplantation and even used in recurrent miscarriage patients, the addition of CsA for the management of preeclampsia has not been reported. In our previous study, we used LPS to successfully induce preeclampsia in a rat model, we found significantly increased serum levels of the inflammatory cytokines TNF-α and IL-1β [8]. Since preeclampsia is associated with increased circulating inflammatory cytokines, it is possible that CsA may down regulate the immune system to decrease inflammatory cytokines and attenuate preeclampsia signs. Therefore, in the present study, we hypothesized that administration of CsA could reduce systolic blood pressure, urinary albumin and proinflammatory cytokines to restore the Th1/Th2 imbalance in the LPS induced rat model of preeclampsia.

Section snippets

Animals

The Guangzhou Medical University Animal Ethics Committee approved all of the experimental protocols. Sprague-Dawley (SD) rats were purchased from the Medical Experimental Animal Center of Guangdong. Rats were housed in a standard laboratory condition (temperature 23–26 °C, relative humidity 50–60%, illumination between 06:00 am and 06:00 pm) with free access to pellet food and water.

Reagents

LPS (strain Escherichia coli 055:B5, Sigma-Aldrich, St. Louis, MO) and CsA (SandimmunNeoral, Novartis, Switzerland)

Systolic blood pressure

The SBP values in NPC and PC did not change significantly during the study period. There were no significant differences in the SBP values among the 5 groups on GD14 before infusion of LPS or saline solution, but it increased significantly on day 16 after infusion with 1 μg/kg LPS. The higher SBP values in the PE group persisted during the pregnancy. The SBP on GD16 and GD19 in PE group were 124.1 ± 1.2 mmHg and 125 ± 1.4 mmHg. The SBP in PE + CsA5 and PE + CsA10 group were 128.3 ± 1.6 mmHg and 125.4 ± 1.1 mmHg

Discussion

Preeclampsia is a condition characterized by increased inflammatory cytokines. In the present study, we investigated the effects of CsA in a LPS-induced PE model and found that CsA attenuated the LPS-mediated hypertension and urinary proteinuria excretion. In addition, we demonstrated that CsA significantly decreased levels of IL-6, IL-17, IFN-γ and TNF-α that were increased in PE model. In contrast, IL-4 was reduced in the PE model but was increased after CsA treatment.

Recent studies support

Acknowledgments

The authors thank Lijun Dai, Chengjie Liang in Guangzhou Medical University for the help with the animal experiments. This study was supported by Grants from the National Natural Sciences Foundation of China (81170594, 30471828, and 30973206).

References (28)

  • P. Cochat

    Renal outcome of children exposed to cyclosporine in utero

    Transpl. Proc.

    (2004)
  • M.R. Du

    Cyclosporin a improves pregnancy outcome by promoting functions of trophoblasts and inducing maternal tolerance to the allogeneic fetus in abortion-prone matings in the mouse

    Biol. Reprod.

    (2007)
  • V. Germano

    Cyclosporine a in the long-term management of systemic lupus erythematosus

    J. Biol. Regul. Homeost. Agents

    (2011)
  • M.L. Hetland

    Modern treatment strategies in rheumatoid arthritis

    Dan. Med. Bull.

    (2011)
  • Cited by (11)

    • Acute systemic inhibition of inflammation augments endothelium-dependent dilation in women with a history of preeclamptic pregnancy

      2022, Pregnancy Hypertension
      Citation Excerpt :

      This immune imbalance creates a chronic and uncontrolled state of inflammation which likely initiates and perpetuates the wide-spread endothelial dysfunction in the peripheral, glomerular, and cerebral vessels of preeclamptic women [26,27]. In support of this hypothesis, immunosuppression with cyclosporin A improves clinical characteristics of preeclampsia in a lipopolysaccharide induced preeclampsia rat model [28]. Specifically, in the reduced uterine perfusion pressure rat model of preeclampsia, tumor necrosis factor alpha (TNFα) blockade lowers blood pressure and improves organ function [29].

    • Cyclosporin A alleviates trophoblast apoptosis and senescence by promoting autophagy in preeclampsia

      2022, Placenta
      Citation Excerpt :

      Meanwhile, CsA could improve the imbalance of pro-angiogenic (the downregulation of VEGFA) and anti-angiogenic (the upregulation of sFlt-1) factors induced by l-NAME. Several previous studies have also demonstrated the therapeutic effect of CsA in PE-like mice; for instance, Hu et al. found that CsA plays an immunosuppressive role in rats with lipopolysaccharide (LPS)-induced PE by decreasing the expression of pro-inflammatory cytokines (IL-6, IL-17, IFN-γ, and TNF-α) [47]. Similarly, Huang et al. injected pregnant rats with LPS and the epileptogenic drug pentylenetetrazol (PTZ) to establish an eclampsia-like model, finding that CsA reduced symptoms such as hypertension and proteinuria while also decreasing seizure scores and prolonging seizure latency [48].

    • Cys-peptide mediates the protective role in preeclampsia-like rat and cell models

      2020, Life Sciences
      Citation Excerpt :

      However, Cys-peptide attenuated LPS-induced hypertension and proteinuria symptoms. FGR, as we know, is one of important adverse effects of PE on offspring [29,30]. In our study, the incidence rate of FGR significantly declined after injection of Cys-peptide in PE rat model, which may be associated with the placental utilization rate decreased in the PE model but increased after Cys-peptide treatment.

    • Maternal Micronutrients, Omega-3 Fatty Acids and Gene Expression of Angiogenic and Inflammatory Markers in Pregnancy Induced Hypertension Rats

      2017, Archives of Medical Research
      Citation Excerpt :

      It originates in the placenta and is one of the most common causes of preterm birth and fetal growth restriction (2). It is believed that ‘excessive inflammation’ and ‘angiogenic imbalance’ is associated with PE (3–6). Maternal nutrition has been shown to influence the susceptibility of the offspring's genome to complex diseases in adulthood (7).

    • Activation of the cholinergic anti-inflammatory pathway by nicotine ameliorates lipopolysaccharide-induced preeclampsia-like symptoms in pregnant rats

      2017, Placenta
      Citation Excerpt :

      In a previous study, we reported that treatment with MgSO4 significantly decreased TNF-α and IL-1β levels and increased the seizure threshold in LPS-induced PE model rats. Cyclosporine A, an immunosuppressant, improved the symptoms of PE and attenuated inflammatory responses in this rat model [23,33]. These data suggest that anti-inflammatory agents could improve the clinical characteristics of PE in rat models by attenuating inflammatory responses.

    View all citing articles on Scopus
    View full text